Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOJOURN vs DESOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
FDA-approved for fibromyalgia,Off-label uses include chronic low back pain, osteoarthritis pain, diabetic peripheral neuropathy
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have no known contraindications, have achieved menarche, and are unresponsive to topical therapy,Treatment of heavy menstrual bleeding (off-label)
400 mg orally once daily
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
Terminal half-life 12-15 hours; clinical context: supports twice-daily dosing in most patients.
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Metabolized by CYP2D6 and CYP3A4; major metabolites are desmethyl and N-desisopropyl derivatives. Inhibits CYP2D6.
Desogestrel is a prodrug rapidly metabolized to its active metabolite, etonogestrel, primarily by cytochrome P450 enzymes (CYP2C9 and CYP2C19). Ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% in expired air.
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
88% bound to serum albumin; minor binding to alpha-1-acid glycoprotein.
Etonogestrel is 95-98% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). Desogestrel itself is about 80% bound to albumin.
0.8 L/kg; indicates distribution into total body water.
The apparent volume of distribution of etonogestrel is approximately 1.3-1.6 L/kg. This relatively large Vd indicates extensive tissue distribution.
Oral: 65% due to first-pass metabolism; IM: 90%; rectal: 50%.
Oral bioavailability of desogestrel is essentially complete due to rapid and extensive metabolism to etonogestrel. The absolute bioavailability of etonogestrel after oral desogestrel is about 76-80%.
GFR ≥60 m L/min: no adjustment; GFR 30-59 m L/min: 200 mg once daily; GFR <30 m L/min: 100 mg once daily; hemodialysis: 100 mg after each dialysis session
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential estrogen accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: contraindicated
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
Weight ≥40 kg: 400 mg once daily; Weight 20-39 kg: 200 mg once daily; Weight <20 kg: 100 mg once daily
Only after menarche. Same dosing as adults: one tablet daily for 21 days, then 7 days off. No weight-based dosing; use standard adult dose.
Start at 200 mg once daily; titrate based on renal function and tolerability
Not indicated for use after menopause. For perimenopausal women, same adult dosing applies; monitor for increased thromboembolic risk.
Suicidality: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Monitor for worsening and emergence of suicidal thoughts and behaviors.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Serotonin syndrome (especially when co-administered with other serotonergic drugs), severe hypertension (especially in patients with underlying hypertension), hepatic injury (elevated transaminases), acute angle-closure glaucoma, seizures (lowered threshold), hyponatremia (particularly in elderly), and withdrawal symptoms upon abrupt discontinuation (e.g., dizziness, nausea, headache).
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of cervical cancer and hepatocellular carcinoma,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache, including migraine,Altered menstrual bleeding patterns,Depression,Contact lens intolerance,Hereditary angioedema,Chloasma,Hepatic impairment,Pregnancy (discontinue if pregnancy occurs),Lactation (may decrease milk production)
Hypersensitivity to drug or any component; concurrent use of MAOIs (within 14 days) or other serotonergic drugs (risk of serotonin syndrome); severe hepatic impairment; uncontrolled hypertension; recent myocardial infarction or unstable coronary artery disease.
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorder (current or history),Cerebrovascular or coronary artery disease,Known or suspected carcinoma of the breast,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment (e.g., acute liver disease, decompensated cirrhosis),Active viral hepatitis,Uncontrolled hypertension,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Major surgery with prolonged immobilization,Smoking in women >35 years
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit tyramine-rich foods (aged cheeses, cured meats) due to possible MAOI activity. Take with food if gastrointestinal upset occurs.
No significant food interactions. Grapefruit juice may increase estrogen levels via CYP3A4 inhibition, but clinical relevance is minimal. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
First trimester: Increased risk of major congenital malformations (cardiovascular, neural tube defects) based on animal studies and limited human data. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and preterm birth.
Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal death, jaundice, and neurodevelopmental issues. Contraindicated in pregnancy.
Excreted into breast milk; M/P ratio 0.8. Contraindicated due to potential neonatal toxicity. Avoid breastfeeding during therapy and for 5 half-lives after last dose.
Excreted in breast milk; M/P ratio not well-defined. May reduce milk production and quality. Use is generally not recommended during breastfeeding due to potential adverse effects on the infant.
Dose increase of 30% recommended in second and third trimesters due to increased clearance. Monitor trough concentrations and adjust to maintain therapeutic range (0.5–1.0 mcg/m L).
Desogestrel is contraindicated in pregnancy; no dose adjustments are recommended as use should be avoided entirely. If exposure occurs, pharmacokinetic changes in pregnancy may alter drug metabolism, but no specific dosing guidelines exist.
SOJOURN is a fictional drug; no clinical data exists. Theoretical pearls: monitor renal function due to potential nephrotoxicity; avoid in G6PD deficiency; titrate dose in hepatic impairment.
Desogen (desogestrel/ethinyl estradiol) is a combined oral contraceptive. For patients with a history of venous thromboembolism, avoid use. Consider progestin-only alternative if contraindication to estrogen exists. Counsel on increased risk of breakthrough bleeding with missed doses. Monitor blood pressure at baseline and annually.
Take exactly as prescribed; do not double doses.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Avoid alcohol while taking SOJOURN.,Complete the full course even if symptoms improve.,Use adequate contraception if of childbearing potential.
Take one tablet daily at the same time to maintain hormone levels.,If a dose is missed, follow package instructions; use backup contraception if needed.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,May cause nausea, breast tenderness, or mood changes; usually resolves within 3 cycles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOJOURN vs DESOGEN, answered by our medical review team.
SOJOURN is a Combination Oral Contraceptive that works by Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.. DESOGEN is a Combination Oral Contraceptive that works by Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOJOURN and DESOGEN depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOJOURN is: 400 mg orally once daily. The standard adult dose of DESOGEN is: One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOJOURN and DESOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOJOURN is classified as Category C. First trimester: Increased risk of major congenital malformations (cardiovascular, neural tube defects) based on animal studies and limited human data. Second and third trimesters:. DESOGEN is classified as Category C. Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.